Bianchi Laura, Gagliardi Assunta, Maruelli Silvia, Besio Roberta, Landi Claudia, Gioia Roberta, Kozloff Kenneth M, Khoury Basma M, Coucke Paul J, Symoens Sofie, Marini Joan C, Rossi Antonio, Bini Luca, Forlino Antonella
Functional Proteomics Laboratory, Department of Life Sciences, University of Siena, Siena, Italy.
Department of Molecular Medicine, Biochemistry Unit, University of Pavia, Pavia, Italy.
Hum Mol Genet. 2015 Nov 1;24(21):6118-33. doi: 10.1093/hmg/ddv328. Epub 2015 Aug 11.
Osteogenesis imperfecta (OI) is a heritable bone disease with dominant and recessive transmission. It is characterized by a wide spectrum of clinical outcomes ranging from very mild to lethal in the perinatal period. The intra- and inter-familiar OI phenotypic variability in the presence of an identical molecular defect is still puzzling to the research field. We used the OI murine model Brtl(+/-) to investigate the molecular basis of OI phenotypic variability. Brtl(+/-) resembles classical dominant OI and shows either a moderately severe or a lethal outcome associated with the same Gly349Cys substitution in the α1 chain of type I collagen. A systems biology approach was used. We took advantage of proteomic pathway analysis to functionally link proteins differentially expressed in bone and skin of Brtl(+/-) mice with different outcomes to define possible phenotype modulators. The skin/bone and bone/skin hybrid networks highlighted three focal proteins: vimentin, stathmin and cofilin-1, belonging to or involved in cytoskeletal organization. Abnormal cytoskeleton was indeed demonstrated by immunohistochemistry to occur only in tissues from Brtl(+/-) lethal mice. The aberrant cytoskeleton affected osteoblast proliferation, collagen deposition, integrin and TGF-β signaling with impairment of bone structural properties. Finally, aberrant cytoskeletal assembly was detected in fibroblasts obtained from lethal, but not from non-lethal, OI patients carrying an identical glycine substitution. Our data demonstrated that compromised cytoskeletal assembly impaired both cell signaling and cellular trafficking in mutant lethal mice, altering bone properties. These results point to the cytoskeleton as a phenotypic modulator and potential novel target for OI treatment.
成骨不全症(OI)是一种具有显性和隐性遗传方式的遗传性骨病。其临床症状范围广泛,从非常轻微到围生期致死不等。在存在相同分子缺陷的情况下,家族内和家族间的OI表型变异性仍然是该研究领域的一个难题。我们使用OI小鼠模型Brtl(+/-)来研究OI表型变异性的分子基础。Brtl(+/-)类似于经典的显性OI,并且在I型胶原α1链中相同的甘氨酸349半胱氨酸替代与中度严重或致死性结果相关。我们采用了系统生物学方法。利用蛋白质组学通路分析将在具有不同结果的Brtl(+/-)小鼠的骨骼和皮肤中差异表达的蛋白质进行功能关联,以确定可能的表型调节因子。皮肤/骨骼和骨骼/皮肤混合网络突出了三种关键蛋白质:波形蛋白、微管相关蛋白和丝切蛋白-1,它们属于细胞骨架组织或参与细胞骨架组织。免疫组织化学确实证明,异常的细胞骨架仅在Brtl(+/-)致死小鼠的组织中出现。异常的细胞骨架影响成骨细胞增殖、胶原蛋白沉积、整合素和TGF-β信号传导,损害骨骼结构特性。最后,在从携带相同甘氨酸替代的致死性而非非致死性OI患者获得的成纤维细胞中检测到异常的细胞骨架组装。我们的数据表明,受损的细胞骨架组装损害了突变致死小鼠中的细胞信号传导和细胞运输,改变了骨骼特性。这些结果表明细胞骨架是一种表型调节因子,也是OI治疗的潜在新靶点。